Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

19 February 2025 : Case report  Grenada

Extragastrointestinal Stromal Tumor Mimicking Appendicitis: A Case Study

Unusual clinical course, Challenging differential diagnosis, Rare coexistence of disease or pathology

Ricardo Martinez ABDEFG 1, Michael Lezcano ABDEFG 1, Jonak Randhawa ABDEFG 1, Shahryar Aijaz ABDEFG 1, Yara Al Mazouni ABDEFG 1, Ahmed Altamimi ABDEFG 2,3*, Norka Camacho-Perez ABDEFG 1, Feras Othman ABDEFG 4, Andrew M. O'Neill ACD 3, Joshua A. Simon BCD 3

DOI: 10.12659/AJCR.944665

Am J Case Rep 2025; 26:e944665

Table 1. Follow-up of gastrointestinal stromal tumor (GIST) patients treated with surgery alone [19].

Risk groupRecurrence risk evaluation methodFollow-up recommendation
Modified National Institutes of Health schemeArmed Forces Institute of Pathology (AFIP) schemePrognostic heat maps
Very low risk≤2.0 cm, ≤5 mitoses/50 high power fields (HPFs), any tumor siteGroup 10–10%Likely cured by surgery. No regular follow-up
Low risk2.1–5.0 cm, ≤5 mitoses/50 HPFs, any tumor siteGroup 20–10%No follow-up; OR abdominal/pelvic computerized tomography (CT)/magnetic resonance imaging (MRI) annually for approximately 5 years
Intermediate risk≤2.0 cm, 6–10 mitoses/50 HPFs, gastric tumor OR 5.1–10.0 cm, ≤5 mitoses/50 HPFs, gastric tumorGroup 3a10–20%Abdominal/pelvic CT/MRI annually for approximately 5 years, the first scan approximately 6–8 months after surgery
High risk The rest of the patients; any patient with tumor ruptureGroups 3b, 4, 5, 6a, 6b30–100%Abdominal CT/MRI 6-monthly for the first 5 years, then annually for the next 5 years (the total duration of follow-up is 10 years after surgery)
* Patients with a high estimated risk for GIST recurrence should be treated with adjuvant imatinib, and they are recommended to be followed up as shown in . The recommendations shown in apply only to high-risk patients whose GIST contains a mutation that confers imatinib resistance (notably exon 18 mutation D842V) or is wild-type for and .

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923